<- Go Home
GlycoMimetics, Inc.
As of June 13, 2025, GlycoMimetics, Inc. was acquired by Crescent Biopharma, Inc., in a reverse merger transaction. GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland.
Market Cap
$10.1M
Volume
67.5K
Cash and Equivalents
$5.6M
EBITDA
-$23.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$63.00
52 Week Low
$14.06
Dividend
N/A
Price / Book Value
3.00
Price / Earnings
-0.34
Price / Tangible Book Value
3.00
Enterprise Value
$4.5M
Enterprise Value / EBITDA
-0.19
Operating Income
-$23.8M
Return on Equity
182.66%
Return on Assets
-73.99
Cash and Short Term Investments
$5.6M
Debt
N/A
Equity
$3.4M
Revenue
N/A
Unlevered FCF
-$11.3M
Sector
Biotechnology
Category
N/A